The management of Familial Exudative Vitreoretinopathy (FEVR) is highly individualized, depending on the severity and stage of the disease. While there is currently no cure that can reverse the genetic cause of FEVR, a range of treatments is available to manage symptoms, prevent complications, and preserve vision.
In the early stages of FEVR, where the peripheral retina lacks blood vessels but no abnormal vessels have formed, close observation may be all that is required. However, if abnormal, leaky blood vessels (neovascularization) begin to develop, intervention becomes necessary. The primary treatment at this stage is laser photocoagulation. This procedure uses a laser to create tiny burns in the avascular peripheral retina, which reduces the oxygen demand and halts the production of growth factors that stimulate abnormal vessel growth.
In some cases, particularly when there is significant fluid leakage (exudation) or inflammation, doctors may use injections of anti-vascular endothelial growth factor (anti-VEGF) medications or steroids into the eye. These medications help reduce swelling and abnormal vessel growth, often serving as an adjunct to laser therapy.
For more advanced stages of FEVR, where scar tissue has formed and caused the retina to detach, surgical intervention is required. Procedures such as scleral buckling (placing a flexible band around the eye to support the retina) or vitrectomy (removing the vitreous gel and scar tissue pulling on the retina) are performed to reattach the retina and stabilize vision. These surgeries are complex and are typically performed by highly specialized retina surgeons.
Looking to the future, the treatment paradigm for FEVR is poised for a significant shift. Current therapies are reactive, aiming to control the damage caused by the disease. However, researchers are developing proactive treatments designed to promote normal blood vessel growth. Experimental therapies, such as synthetic norrin mimics, aim to activate the Wnt signaling pathway to regenerate healthy capillaries in the avascular retina. If successful, these treatments could prevent the cascade of complications before they begin.
As research progresses, the hope is that these pipeline therapies will eventually become standard care, offering a brighter visual prognosis for individuals with FEVR. Patients should regularly consult their healthcare provider to stay informed about the most appropriate current treatments and potential clinical trials.